• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Consort Medical’s Bespak inks Syrina auto-injector development deal

October 14, 2016 By Sarah Faulkner

BespakConsort Medical (LON:CSRT) subsidiary Bespak said today that it inked a development agreement with an undisclosed biopharmaceutical company for its Syrina auto-injector.

The deal makes Bespak responsible for early-stage development of the auto-injector. If the undisclosed partner agrees to commercialize the developed product, both parties will enter into a full commercial supply agreement, the company said.

Rather than using a spring to drive the delivery of a drug, Syrina uses a liquid gas propellant. This alternative technique can deliver a broader range of drug formulations and volumes, while reducing potential for glass syringe breakage, the company reported.

“We are delighted to initiate this collaboration for the development of a Syrina auto-injector product,” CEO Jonathan Glenn said in prepared remarks. “This reinforces Bespak’s position as a leading provider of drug-delivery device solutions. We believe that Syrina and Vapoursoft offer significant opportunities for pharmaceutical and biopharmaceutical companies to develop patient-centric presentations of their drugs.”

In September, AstraZeneca (NYSE:AZN) inked a multi-year commercial supply deal with Bespak for its pressurized metered-dose inhaler technology.

The AstraZeneca deal for Bespak came just months after the FDA delayed its decision date for Consort’s generic Advair inhaler to March 2017, which distracted analysts from their impressive finish in fiscal 2016.

Filed Under: Auto-injectors, Drug-Device Combinations, Research & Development Tagged With: Bespak, Consort Medical

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS